Nov 14 (Reuters) - German drugmaker Evotec is

attracting takeover interest from U.S.-based Halozyme

Therapeutics ( HALO ), Bloomberg News reported on Thursday.

Halozyme has recently expressed interest in acquiring Evotec

at about 11 euros per share, the report added, citing people

familiar with the matter.

Earlier this week private equity firm Triton was also

reportedly exploring a potential buyout of Evotec, after it

confirmed a close to 10% stake in the company.

Evotec's other major shareholders are Novo Nordisk

parent Novo Holdings and Mubadala Investment.

Evotec's shares have fallen about 60% this year as revenues

continue to slump due to weakness in the clinical research

organization business market environment.

The company collaborates with biotech companies through

research alliances and development partnerships to help with

drug development.